Lenetix launches prenatal blood test for Down's syndrome
This article was originally published in Clinica
Lenetix has launched its PloidYX maternal blood test, designed to detect Down’s syndrome and other chromosomal abnormalities in the first and second trimester of pregnancy. The Mineola, New York firm hopes the diagnostic will reduce the number of unnecessary invasive tests, such as amniocentesis or chorionic villus sampling, which carry a risk of miscarriage. Pregnant women undergo these tests if they are deemed to be "at risk" by ultrasound and biochemical exams – however, these can be inaccurate. Lenetix’s test exploits methylation differences between the foetal and maternal DNA in maternal blood, in order to selectively amplify and then analyse the foetal component. Historically, the low number of foetal cells in a maternal blood sample has made it difficult to separate foetal and maternal DNA.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.